VYNE Therapeutics announces dosing of first patient in Phase 1b trial of VYN202

VYNE Therapeutics (VYNE) announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain inhibitor that is being developed for the treatment of immune-mediated diseases. The Phase 1b trial will primarily evaluate the safety of VYN202, administered orally once a day for 12 weeks, with secondary objectives to evaluate the pharmacokinetic profile and preliminary evidence of efficacy, including improvement from baseline in psoriasis area and severity index scores. Top-line data from the 12-week randomized, placebo-controlled trial are expected by year-end 2025.